Speaking in past tense

In his 19-year tenure as president and CEO of Medarex Inc., Donald Drakeman took the company from startup to a $1.6 billion company with 33 antibodies in the clinic, either alone or with partners. But following his resignation in the midst of an ongoing investigation into backdated stock options, investors are betting that MEDX's future is not tied to that of its former chief. Indeed, the stock added $0.80 to $12.99 last week on the news.

Although details aren't being disclosed, the investigation apparently includes a period during which some company officers realized more than $40 million in gains

Read the full 990 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE